Answer
The most frequently reported adverse reactions to satralizumab were headache (19.2%), arthralgia (13.5%), decreased white blood cell count (13.5%), hyperlipidaemia (13.5%) and injection-related reactions (12.5%).
Sources for this answer
- Enspryng 120 mg solution for injection in pre-filled syringeRoche Products Limited · emc · SmPC §4.8 Undesirable effects · Version 3Document updated
Sources checked